Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$133.73
+3.7%
$129.87
$110.04
$207.59
$19.66B0.131.56 million shs750,731 shs
Netflix, Inc. stock logo
NFLX
Netflix
$1,213.73
-0.9%
$1,232.39
$648.70
$1,341.15
$515.74B1.594.18 million shs1.55 million shs
NIKE, Inc. stock logo
NKE
NIKE
$77.24
+3.1%
$70.20
$52.28
$90.62
$114.09B1.2716.97 million shs7.81 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
+0.73%-2.98%-3.93%+7.11%-35.87%
Netflix, Inc. stock logo
NFLX
Netflix
+0.57%+6.74%-1.59%+6.45%+93.52%
NIKE, Inc. stock logo
NKE
NIKE
+1.14%+0.67%+3.10%+21.27%+0.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biogen Inc. stock logo
BIIB
Biogen
4.9055 of 5 stars
4.24.00.03.72.72.52.5
Netflix, Inc. stock logo
NFLX
Netflix
4.458 of 5 stars
2.35.00.02.84.02.51.9
NIKE, Inc. stock logo
NKE
NIKE
4.5003 of 5 stars
2.44.04.21.53.62.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.34
Hold$185.6338.81% Upside
Netflix, Inc. stock logo
NFLX
Netflix
2.58
Moderate Buy$1,297.666.91% Upside
NIKE, Inc. stock logo
NKE
NIKE
2.72
Moderate Buy$78.221.28% Upside

Current Analyst Ratings Breakdown

Latest BIIB, NKE, and NFLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
Netflix, Inc. stock logo
NFLX
Netflix
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/1/2025
Biogen Inc. stock logo
BIIB
Biogen
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$125.00 ➝ $135.00
8/1/2025
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$208.00 ➝ $219.00
8/1/2025
Biogen Inc. stock logo
BIIB
Biogen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$146.00 ➝ $144.00
8/1/2025
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$187.00 ➝ $194.00
7/28/2025
NIKE, Inc. stock logo
NKE
NIKE
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$64.00 ➝ $93.00
7/21/2025
Netflix, Inc. stock logo
NFLX
Netflix
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/21/2025
Biogen Inc. stock logo
BIIB
Biogen
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$142.00
7/21/2025
Netflix, Inc. stock logo
NFLX
Netflix
Phillip Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/21/2025
Netflix, Inc. stock logo
NFLX
Netflix
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$1,300.00 ➝ $1,500.00
7/19/2025
Netflix, Inc. stock logo
NFLX
Netflix
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Underperform ➝ Market Underperform
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.68B2.03$24.14 per share5.54$120.28 per share1.11
Netflix, Inc. stock logo
NFLX
Netflix
$39.00B13.22$56.69 per share21.41$58.72 per share20.67
NIKE, Inc. stock logo
NKE
NIKE
$46.31B2.46$2.85 per share27.13$8.95 per share8.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$10.4612.828.101.0115.31%13.85%8.32%10/29/2025 (Estimated)
Netflix, Inc. stock logo
NFLX
Netflix
$8.71B$23.4751.7140.962.0524.58%42.50%19.42%10/16/2025 (Estimated)
NIKE, Inc. stock logo
NKE
NIKE
$3.22B$2.1635.7633.012.696.95%23.33%8.57%10/7/2025 (Estimated)

Latest BIIB, NKE, and NFLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
Biogen Inc. stock logo
BIIB
Biogen
$3.93$5.47+$1.54$4.33$2.32 billion$2.65 billion
7/17/2025Q2 2025
Netflix, Inc. stock logo
NFLX
Netflix
$7.07$7.19+$0.12$7.19$11.04 billion$11.08 billion
6/26/2025Q4 2025
NIKE, Inc. stock logo
NKE
NIKE
$0.12$0.14+$0.02$0.14$10.69 billion$11.10 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Netflix, Inc. stock logo
NFLX
Netflix
N/AN/AN/AN/AN/A
NIKE, Inc. stock logo
NKE
NIKE
$1.602.07%N/A74.07%22 Years

Latest BIIB, NKE, and NFLX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/7/2025
NIKE, Inc. stock logo
NKE
NIKE
quarterly$0.402.15%9/2/20259/2/202510/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.36
2.50
1.79
Netflix, Inc. stock logo
NFLX
Netflix
0.58
1.34
1.34
NIKE, Inc. stock logo
NKE
NIKE
0.60
2.21
1.50

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Netflix, Inc. stock logo
NFLX
Netflix
80.93%
NIKE, Inc. stock logo
NKE
NIKE
64.25%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.18%
Netflix, Inc. stock logo
NFLX
Netflix
1.37%
NIKE, Inc. stock logo
NKE
NIKE
0.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,605146.62 million146.35 millionOptionable
Netflix, Inc. stock logo
NFLX
Netflix
14,000424.93 million419.11 millionOptionable
NIKE, Inc. stock logo
NKE
NIKE
77,8001.48 billion1.47 billionOptionable

Recent News About These Companies

AIA Group Ltd Sells 15,297 Shares of NIKE, Inc. (NYSE:NKE)
Invesco Ltd. Buys 1,103,281 Shares of NIKE, Inc. (NYSE:NKE)
Nike partners with iconic retailer on special events

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biogen stock logo

Biogen NASDAQ:BIIB

$133.72 +4.80 (+3.72%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Netflix stock logo

Netflix NASDAQ:NFLX

$1,213.73 -11.55 (-0.94%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Netflix, Inc. provides entertainment services. It offers TV series, documentaries, feature films, and games across various genres and languages. The company also provides members the ability to receive streaming content through a host of internet-connected devices, including TVs, digital video players, TV set-top boxes, and mobile devices. It has operations in approximately 190 countries. The company was incorporated in 1997 and is headquartered in Los Gatos, California.

NIKE stock logo

NIKE NYSE:NKE

$77.24 +2.34 (+3.12%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells athletic footwear, apparel, equipment, accessories, and services worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. It also sells a line of performance equipment and accessories comprising bags, sport balls, socks, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. In addition, the company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel; and licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. It sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.